Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.75 USD
Change Today -0.11 / -2.26%
Volume 187.0K
NEO On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/10/14 - $6.10
52 Week Low
05/9/14 - $2.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to localize proteins in cells of a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

440 Employees
Last Reported Date: 03/3/15
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $557.0K
Chief Financial Officer
Total Annual Compensation: $305.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $92.5K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $72.5K
Compensation as of Fiscal Year 2013.

neogenomics inc (NEO) Key Developments

Neogenomics Announces Promotions of Senior Management Team

Neogenomics Inc. announced several promotions within the company's senior management team. Sally Agersborg, M.D., Ph.D., Director of Hematopathology and Medical Director, Irvine. Dr. Agersborg joined NeoGenomics in 2011 as a Hematopathologist and currently serves as Medical Director, Irvine. Prior to joining NeoGenomics, Dr. Agersborg worked as a Hematopathologist at Quest Diagnostics Nichols Institute. Jennifer Balliet, Vice President of Human Resources. Jennifer joined NeoGenomics in 2008 and has steadily increased her responsibilities and importance to company and currently serves as Director of HR. Steven Brodie, Ph.D., Chief Scientific Officer and Medical Director, Fort Myers. Dr. Brodie joined NeoGenomics in 2011 as Director of Cytogenetics in Fort Myers and currently serves as Director of Molecular Genetics and Cytogenetics, Florida. Prior to joining NeoGenomics, he served as Senior Director of Cytogenetics, and Assistant Director of Molecular Genetics at Specialty Laboratories/Quest Diagnostics in Valencia CA.

NeoGenomics, Inc. Announces Executive Changes

NeoGenomics Inc. announced that Dr. Steven Brodie, age 54, was named as chief scientific officer of the company. Dr. Brodie will serve until the earlier of his replacement or resignation. Dr. Brodie continues to be Laboratory Director for the company's Fort Myers facility, a role he has held since 2014 and he also continues to be the company's director of Molecular Genetics and Cytogenetics, a role he has held since 2011. Prior to joining NeoGenomics Laboratories, the company's wholly-owned subsidiary, Dr. Brodie served as a senior director of Cytogenetics, Assistant Director of Molecular Genetics, and scientific director of Maternal Serum Screening at Quest Diagnostics (Specialty Laboratories) in Valencia, California. Jennifer Balliet, age 37, was also appointed as vice president of human resources of the company to serve to the earlier of her replacement or resignation. Mrs. Balliet joined the company in 2008 and has been serving as director of human resources. As vice president of human resources, Mrs. Balliet will have responsibility for the oversight of all areas of the company’s human resources including recruiting, training, development, compensation, incentive plans and organizational development.

Neogenomics Inc. Reports Consolidated Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for 2015

Neogenomics Inc. reported consolidated unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net revenue was $25,000,000 against $18,323,000 a year ago. Income from operations was $1,319,000 against $1,204,000 a year ago. Income before taxes was $1,126,000 against $963,000 a year ago. Net income was $1,047,000 against $857,000 a year ago. Diluted per share was $0.02 against $0.02 a year ago. EBITDA was $2,820,000 against $2,334,000 a year ago.  Adjusted EBITDA (non-GAAP) was $2,773,000 against $2,733,000 a year ago. For the year, the company reported net revenue was $87,069,000 against $66,467,000 a year ago. Income from operations was $2,218,000 against $3,174,000 a year ago. Income before taxes was $1,289,000 against $2,185,000 a year ago. Net income was $1,132,000 against $2,033,000 a year ago. Diluted per share was $0.02 against $0.04 a year ago. Net cash provided from operating activities was $9,450,000 against $2,227,000 a year ago. EBITDA was $7,914,000 against $7,586,000 a year ago. Adjusted EBITDA (non-GAAP) was $9,176,000 against $8,515,000 a year ago. The company expects 2015 revenue of $103 - $108 million. This guidance includes an estimated $6 - $8 million reduction in revenue from all payers as a result of billing the new AMA FISH CPT codes that were effective as of January 1, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $4.75 USD -0.11

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $23.09 USD -0.29
Enzo Biochem Inc $3.01 USD -0.02
Psychemedics Corp $17.66 USD +0.3659
Response Genetics Inc $0.29 USD -0.002
Rosetta Genomics Ltd $3.72 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation NEO Industry Range
Price/Earnings 100.0x
Price/Sales 3.3x
Price/Book 4.7x
Price/Cash Flow 252.8x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at